|
Patients
|
Classification
|
Age at onset of treatment (months)
|
Before treatment
|
After treatment
|
|---|
| | | |
Testes position
|
Penile length (mm)
|
Time to descent (months)
|
Testes volume (ml)
|
Testes position
|
Penile length (mm)
|
Duration of treatment (months)
|
|
P1
|
CPHD
|
6
|
Non palpable
|
18
|
1
|
0.61
|
High scrotal
|
30
|
6
|
|
P2
|
CPHD
|
11
|
Non palpable
|
20
|
4
|
2
|
Intra-scrotal
|
33
|
6
|
|
P3
|
CPHD
|
10
|
High-scrotal
|
30
|
1
|
2,1
|
Intra-scrotal
|
70
|
6
|
|
P4
|
IHH
|
4.5
|
Non palpable
|
21
|
4
|
0.76
|
Intra-scrotal
|
30
|
6.5
|
|
P5
|
IHH
|
2.5
|
Non palpable
|
20
|
6
|
0.7
|
High-scrotal Intra-scrotal
|
35
|
6.5
|
|
P6
|
IHH
|
9
|
Non palpable
|
19
|
4
|
1,16
|
Intra-scrotal
|
40
|
5
|
|
P7
|
IHH
|
5
|
High-scrotal
|
28
|
4
|
0,89
|
Intra-scrotal
|
52
|
5
|
|
P8
|
IHH
|
0.25
|
High-scrotal
|
13
|
5
|
1,95
|
Intra-scrotal
|
30
|
6
|
-
IHH isolated hypogonadotropic hypogonadism, CPHD Combined Pituitary Hormonal Deficits (CPHD)
